Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001<IC 50 <1 μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.
性状
Solid
IC50 & Target[1][2]
c-Kit <1 μM (IC50) c-kit D816V <1 μM
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
ClinicalTrial
参考文献
[1]. Guoxian Wu, et al. Preparation of phenylpyrrolopyridinylheteroarylcarboxamide derivatives and analogs for use as c-kit protein kinases or mutant c-kit protein kinases modulators. Patent WO2014100620 A2.[2]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
溶解度数据
In Vitro: DMSO : 80 mg/mL (241.42 mM; Need ultrasonic)配制储备液